Skip to main content
SpringerLink
Log in

The Role of Clinical Pharmacology and of Pharmacokinetics in The Development of Alendronate - A Bone Resorption Inhibitor

  • Chapter
Applications of Pharmacokinetic Principles in Drug Development

Abstract

The skeleton is the central architectural feature of vertebrates: It distinguishes them from other creatures, it provides structural support and protection to important soft tissues, and it serves as mechanical pivot and provides the mechanical advantage to muscles that makes possible the versatility of movement characteristic of these organisms. In addition to its mechanical functions, bone tissue, which constitutes the bulk of the skeletal mass, carries out various physiological functions. Amongst these, hematopoiesis and mineral metabolism stand out.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cooper, C.: Bone Mass Throughout Life: Bone Growth and Involution, In: Osteoporosis, Pathogenesis and Management, Chapter I, Francis, R. M., ed., Kluwer Academic Publishers, Boston, pp. 1–26, 1990.

    Google Scholar 

  2. Nordin, B. E. C.: Osteoporosis with Particular Reference to the Menopause in the Osteoporotic Syndrome Detection, Prevention, and Treatment (Avioli, L.V., Ed.) Grime and Stratton, N. Y., 1983, Ch. 2.

    Google Scholar 

  3. The Merck Manual, 15th Ed. (Berkow, R., Fletcher, A. V., Eds.) Merck, Sharp & Dohme Res. Lab., Rahway, NJ, 1987, ch. 112.

    Google Scholar 

  4. Christiansen, C., The different routes of administration and the effect of hormone replacement therapy on osteoporosis. Fertil. Steril. 1994 Dec; 62(6 Suppl 2): 152S–156S

    PubMed  CAS  Google Scholar 

  5. Alden, J. C., Osteoporosis--a Review. Clin. Ther. 1989; 11(1): 3–14

    CAS  Google Scholar 

  6. Orwoll, E. S.: Oviatt, S. K.; McClung, M. R.;,Deftos, L. J. and Sexton, G.: The Rate of Bone Mineral Loss in Normal Men and the Effects of Calcium and Cholecalciferol Supplementation. Annals of Internal Medicine 112(1): 29–34, 1990.

    PubMed  CAS  Google Scholar 

  7. Riis, B.; Thomsen, K., and Christiansen, C.: Does Calcium Supplementation Prevent Postmenopausal Bone Loss? A Double-Blind, Controlled Clinical Study. New Eng. J. Med. 316(4): 173–177, 1987.

    CAS  Google Scholar 

  8. Overgaard, K.; Riis, B. J.; Christiansen, C., and Hansen, M. A.: Effect of Salcatonin Given Intranasally on Early Postmenopausal Bone Loss. Brit. Med. J. 299: 477–479, 1989.

    PubMed  CAS  Google Scholar 

  9. Grady, D.; Rubin, S. M.; Petitti, D. B.; Fox, C. S.; Black, D.; Ettinger, B.; Ernster, V. L., and Cummings, S. R.: Hormone Therapy to Prevent Disease and Prolong Life in Postmenopausal Women. Ann. of Int. Med. 117(12): 1016–1037, 1992.

    CAS  Google Scholar 

  10. Jacobs, H. S. and Loeffler, F. E.: Postmenopausal Hormone Replacement Therapy. Brit. Med. J. 305: 1403–1408, 1992.

    PubMed  CAS  Google Scholar 

  11. Barrett-Connor, E.: Risks and Benefits of Replacement Estrogen. Ann. Rev. Med. 43: 239–251, 1992.

    PubMed  CAS  Google Scholar 

  12. Prestwood,KM; Pilbeam,CC, and Raisz,LG, Treatment of Osteoporosis., Ann. Rev. Med. 1995; 46: 24956

    Google Scholar 

  13. Cooper, C. and Melton, L.J., Epidemiology of Osteoporosis., Trends Endocrinol. Metab. 3(6): 224–229, 1992

    CAS  Google Scholar 

  14. Cummings, S.R., Rubin, S.M., Black, D., The Future of Hip Fractures in the United States. Numbers, Costs, and Potential Effects of Postmenopausal Estrogen., Clin. Orthop. 1990 Mar., (252): 163–6

    Google Scholar 

  15. Avioli, L.V., Significance of osteoporosis: a growing international health care problem., Calcif. Tissue. Int. 1991., 49 Suppl: S5–7

    PubMed  Google Scholar 

  16. Riggs, B.L., Melton, L.J 3rd., The prevention and treatment of osteoporosis., N. Engl. J. Med. 1992 Aug 27., 327(9): 620–7

    PubMed  CAS  Google Scholar 

  17. Cooper, C., Wickham, C., Walsh, K., Appendicular skeletal status and hip fracture in the elderly: 14 - year prospective data., Bone. 1991; 12(5): 361–4

    PubMed  CAS  Google Scholar 

  18. Cummings, S.R., Black, D.M., Nevitt, M.C., Browner, W.S., Cauley, J.A., Genant, H.K., Mascioli, S.R., Scott, J.C., Seeley, D.G., Steiger, P., et.al., Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group., JAMA. 1990 Feb 2; 263(5): 665–8

    PubMed  CAS  Google Scholar 

  19. Hui, S.L., Slemenda, C.W., Johnston, C.0 Jr., Age and bone mass as predictors of fracture in a prospective study., J. Clin. Invest. 1988 Jun; 81(6): 1804–9

    CAS  Google Scholar 

  20. Melton, L.J., Chao, E.Y.S. and Lane, J., Biomechanical Aspects of Fracture. Chapter 4, in Osteoporosis, Ethiology, Diagnosis and Management, Riggs, G.L. and Melton, L.J., eds., Raven Press, NY, 1988, pp. 111–131

    Google Scholar 

  21. Barrett-Connor, E., Risks and Benefits of Replacement Estrogen., Annu. Rev. Med. 1992; 43: 239–51

    CAS  Google Scholar 

  22. Lindsay, R., Hart, D.M., Forrest, C. and Baird, C., Prevention of Spinal Osteoporosis in Oophorectomised Women., Lancet. 1980 Nov 29; 2(8205): 1151–4

    PubMed  CAS  Google Scholar 

  23. Ryan, P.J., Harrison, R., Blake, G.M., Fogelman, I., Compliance With Hormone Replacement Therapy (HRT) After Screening For Post Menopausal Osteoporosis., Br. J. Obstet. Gynaecol. 1992 Apr; 99(4): 325–8

    PubMed  CAS  Google Scholar 

  24. U.S. Package Circular for PREMARIN, Physician’s Desk Reference, 2624–2626, 1993

    Google Scholar 

  25. Szucs, J., Horvath, C., Kollin, E., Szathmari, M., Hollo, I., Three-Year Calcitonin Combination Therapy For Postmenopausal Osteoporosis With Crush Fractures of the Spine., Calcif. Tissue. Int. 1992 Jan; 50(1): 7–10

    CAS  Google Scholar 

  26. U.S. Package Circular for MIACALCIN, Physician’s Desk Reference, 2017–2018, 1992

    Google Scholar 

  27. Parfitt, A.M., The Coupling of Bone Formation to Bone Resorption: A Critical Analysis of the Concept and of Its Relevance to the Pathogenesis of Osteoporosis., Metab. Bone. Dis. Relat. Res. 1982; 4(1): 1–6

    PubMed  CAS  Google Scholar 

  28. Balena, R., Toolan, B.C., Shea, M., Markatos, A., Myers, E.R., Lee, S.C., Opas, E.E., Seedor, J.G., Klein, H., Frankenfield, D., et. al., The Effects of 2-Year Treatment With the Aminobisphosphonate Alendronate on Bone Metabolism, Bone istomorphometry, and Bone Strength in Ovariectomized Nonhuman Primates., J. Clin. Invest. 1993 Dec; 92(6): 2577–86

    PubMed  CAS  Google Scholar 

  29. Lauritzen, D B; Balena, R; Shea, M; Seedor, J G; Markatos, A; Le, H M; Toolan, B C; Myers, E R; Rodan, G A; Hayes, W C; Effects of Combined Prostaglandin and Alendronate Treatment on the Histomorphometry and Biomechanical Properties of Bone in Ovariectomized Rats., J Bone Miner Res. 1993 Jul; 8(7): 871 9

    PubMed  Google Scholar 

  30. Weinreb, M; Quartuccio, H; Seedor, J G; Aufdemorte, T B; Brunsvold, M; Chaves, E; Kornman, K S; Rodan, G A; Histomorphometrical Analysis of the Effects of the Bisphosphonate Alendronate on Bone Loss Caused By Experimental Periodontitis in Monkeys., J Periodontal Res. 1994 Jan; 29(1): 35–40

    PubMed  CAS  Google Scholar 

  31. Balena, R; Markatos, A; Seedor, J G; Gentile, M; Stark, C; Peter, C P; Rodan, G A; Long-Term Safety of the Aminobisphosphonate Alendronate in Adult Dogs. II. Histomorphometric Analysis of the L5 Vertebrae., J Pharmacol Exp Ther. 1996 Jan; 276(1): 277–83

    PubMed  Google Scholar 

  32. Peter, C P; Cook, W O; Nunamaker, D M; Provost, M T; Seedor, J G; Rodan, G A; Effect of Alendronate on Fracture Healing and Bone Remodeling in Dogs., J Orthop Res. 1996 Jan; 14(1): 74–9

    PubMed  CAS  Google Scholar 

  33. Reid, I. R; Nicholson, G. C; Weinstein, R. S; Hosking, D. J; Cundy, T; Kotowicz, M. A; Murphy, W. A Jr; Yeap, S; Dufresne, S; Lombardi, A; Musliner, T. A; Thompson, D. E; Yates, A. J Biochemical and Radiologic Improvement in Paget’s Disease of Bone Treated With Alendronate: A Randomized, Placebó-Controlled Trial.

    Google Scholar 

  34. Bone, H. G; Downs, R. W Jr; Tucci, J. R; Harris, S. T; Weinstein, R. S; Licata, A. A; McClung, M. R; Kimmel, D. B; Gertz, B. J; Hale, E; Polvino, W. J., Dose-Response Relationships For Alendronate Treatment in Osteoporotic Elderly Women. Alendronate Elderly Osteoporosis Study Centers.

    Google Scholar 

  35. Chavassieux, P. M; Arlot, M. E; Reda, C; Wei, L; Yates, A. J; Meunier, P. J., Histomorphometric Assessment of the Long-Term Effects of Alendronate on Bone Quality and Remodeling in Patients With Osteoporosis.

    Google Scholar 

  36. McClung, M; Clemmesen, B; Daifotis, A; Gilchrist, N. L; Eisman, J; Weinstein, R. S; Fuleihan. G. el. H; Reda, C; Yates, A. J; Ravn, P., Alendronate Prevents Postmenopausal Bone Loss in Women Without Osteoporosis. A Double-Blind, Randomized, Controlled Trial. Alendronate Osteoporosis Prevention Study Group.

    Google Scholar 

  37. Kanis, J.A., Geusens, P., Christiansen, C., Guidelines for Clinical Trials in Osteoporosis. A Position Paper of the European Foundation for Osteoporosis and Bone Disease., Osteoporos. Int. 1991 Jun., I(3): 182–8

    Google Scholar 

  38. Consensus Development Conference: Diagnosis, Prophylaxis and Treatment of Osteoporosis. Amer. J. Med., 94: 646–650, 1993

    Google Scholar 

  39. Chrischilles, E.A., Butler, C.D., Davis, C.S., Wallace, R.B., A Model of Lifetime Osteoporosis Impact., Arch. Intern. Med. 1991 Oct., 151(10): 2026.32

    PubMed  Google Scholar 

  40. Gardsell, P., Johnell, O., Nilsson, B.E., Gullberg, B., Predicting Various Fragility Fractures in Women By Forearm Bone Densitometry: A Follow-Up Study., Calcif. Tissue. Int. 1993 May; 52(5): 348–53

    CAS  Google Scholar 

  41. Haddaway, M.J., Davie, M.W., McCall, I.W., Bone Mineral Density in Healthy Normal Women and Reproducibility of Measurements in Spine and Hip Using Dual-Energy X-Ray Absorptiometry., Br. J. Radiol. 1992 Mar; 65(771): 213–7

    PubMed  CAS  Google Scholar 

  42. Wuster, C., Duckeck, G., Ugurel, A., Lojen, M., Minne, H.W., Ziegler, R., Bone Mass of Spine and Forearm in Osteoporosis and in German Normals: Influences of Sex, Age and Anthropometric Parameters., Eur. J. Clin. Invest. 1992 May; 22(5): 366–70

    PubMed  CAS  Google Scholar 

  43. Kin, K., Kushida, K., Yamazaki, K., Okamoto, S., Inoue, T., Bone Mineral Density of the Spine in Normal Japanese Subjects Using Dual-Energy X-Ray Absorptiometry: Effect of Obesity and Menopausal Status., Calcif. Tissue. Int. 1991 Aug; 49(2): 101–6

    CAS  Google Scholar 

  44. Steiger, P., Cummings, S.R., Black, D.M., Spencer, N.E., Genant, H.K., Age-Related Decrements in Bone Mineral Density in Women Over 65., J. Bone. Miner. Res. 1992 Jun; 7(6): 625–32

    PubMed  CAS  Google Scholar 

  45. Nordin, B.E., Morris, H.A., Osteoporosis and Vitamin D., J. Cell. Biochem. 1992 May; 49(1): 19–25

    PubMed  CAS  Google Scholar 

  46. Siris, E.S, Miller, P.D, Barrett Connor, E., Faulkner, K.G., Wehren, L.E., Abbott, T.A., Berger, M.L., Santora, A., C., and Sherwood, L.M., Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women: Results from the National Osteoporosis Risk Assessment,.J. Am. Med. Assoc. 2001 Dec 12; 286(22): 2815–22

    CAS  Google Scholar 

  47. Law, M.R., Wald, N.J., Meade, T.W., Strategies For Prevention of Osteoporosis and Hip Fracture., BMJ. 1991 Aug 24; 303(6800): 453–9

    PubMed  CAS  Google Scholar 

  48. Kanis, J.A. and McCloskey, E. V., Epidemiology of Vertebral Osteoporosis., Bone. 1992; 13 Suppl 2: S 110

    Google Scholar 

  49. Simonen, O., Incidence of Femoral Neck Fractures: Senile Osteoporosis in Finland in the Years 1970–1985., Calcif. Tissue. Int. 1991; 49 Suppl: S1970–1985

    PubMed  Google Scholar 

  50. Falch, J.A., Kaastad, T.S., Bohler, G., Espeland, J., Sundsvold, O.J., Secular Increase and Geographical Differences in Hip Fracture Incidence in Norway., Bone. 1993 Jul-Aug; 14(4): 643–5

    CAS  Google Scholar 

  51. Nagant-de-Deuxchaisnes, C., Devogelaer, J. P., Increase in the Incidence of Hip Fractures and of the Ratio of Trochanteric to Cervical Hip Fractures in Belgium., Calcif. Tissue. Int. 1988 Mar; 42(3): 201–3

    CAS  Google Scholar 

  52. Hedlund, R., Lindgren, U., Ahlbom, A., Age-and Sex-Specific Incidence of Femoral Neck and Trochanteric Fractures. An Analysis Based on 20,538 Fractures in Stockholm County, Sweden, 1972–1981., Clin. Orthop. 1987 Sep; (222): 1972–1981

    Google Scholar 

  53. Obrant, K.J., Bengner, U., Johnell, O., Nilsson, B.E., Sembo, I., Increasing Age-Adjusted Risk of Fragility Fractures: A Sign of Increasing Osteoporosis in Successive Generations?, Calcif. Tissue. Int. 1989 Mar; 44(3): 157–67

    CAS  Google Scholar 

  54. Lizaur-Utrilla, A., Puchades-Orts, A., Sanchez-del-Campo, F., Anta-Barrio, J., Gutierrez-Carbonell, P., Epidemiology of Trochanteric Fractures of the Femur in Alicante, Spain, 1974–1982., Clin. Orthop. 1987 May; (218): 1974–1982

    Google Scholar 

  55. Mazzuoli, G.F., Gennari, C., Passen, M., Celi, F.S., Acca, M., Camporeale, A., Pioli, G., Pedrazzoni, M., Incidence of Hip Fracture: An Italian Survey., Osteoporos. Int. 1993; 3 Suppl 1: 8–9

    Google Scholar 

  56. Martin, A.D., Silverthorn, K.G., and Houston, C.S., Age-Specific Increase in Hip Fractures in Canada, Osteoporosis, Crhistiansen, C, Johanse, J.S. AND Riis, B.J. ed, Osteopress ApS, Copenhagen, 1987, PP 111–112

    Google Scholar 

  57. Gennari, C., Epidemiology and Financial Aspects of Osteoporosis., Calcium Reg. and Bone Metabol., 1987, 9:897–899

    Google Scholar 

  58. Lee, C.M., Sidhu, J.S., Pan, K.L., Hip Fracture Incidence in Malaysia 1981–1989., Acta. Orthop. Scand. 1993 Apr; 64(2): 1981–1989

    CAS  Google Scholar 

  59. Cooper, C., Campion, G., Melton, L.J 3rd., Hip Fractures in the Elderly: A World-Wide Projection., Osteoporos. Int. 1992 Nov; 2(6): 285–9

    CAS  Google Scholar 

  60. Cooper, C., Atkinson, E.J., Jacobsen, S.J., O’Fallon, W.M., Melton, L.J 3rd., Population-Based Study of Survival After Osteoporotic Fractures., Am. J. Epidemiol. 1993 May 1; 137(9): 1001–5

    PubMed  CAS  Google Scholar 

  61. Gutyon, A.C. and Hall, J.E. Textbook of medical physiology, 10`1’ Ed., W. B. Saunders Company, Philadelphia, 2000.

    Google Scholar 

  62. Fleisch, H; Russell, R. G; Straumann, F, Effect of Pyrophosphate on Hydroxyapatite and Its Implications in Calcium Homeostasis., Nature. 1966 Nov 26; 212(65): 901–3

    CAS  Google Scholar 

  63. Fleisch, H; Maerki, J; Russell, R. G, Effect of Pyrophosphate on Dissolution of Hydroxyapatite and Its Possible Importance in Calcium Homeostasis., Proc-Soc-Exp-Biol-Med. 1966 Jun; 122(2): 317–20

    PubMed  CAS  Google Scholar 

  64. Fleisch, H; Russell, R. G; Bisaz, S; Casey, P. A; Muhlbauer, R. C, The Influence of Pyrophosphate Analogues (Diphosphonates) on the Precipitation and Dissolution., Calcif. Tissue-Res. 1968; Suppl:l0-l0a

    Google Scholar 

  65. Fleisch, H; Russell, R. G; Francis, M. D, Diphosphonates Inhibit Hydroxyapatite Dissolution In-Vitro and Bone Resorption in Tissue Culture and In-Vivo., Science. 1969 Sep 19; 165(899): 1262–4

    PubMed  CAS  Google Scholar 

  66. Fleisch, H.: Bisphosphonates: Pharmacology and Use in the Treatment of Tumour-Induced Hypercalcaemic and Metastatic Bone Disease. Drug 42(6): 919–944, 1991.

    CAS  Google Scholar 

  67. Bergstrom, J D, Bostedor, R G, Masarachia, P J, Reszka, A A, Rodan, G, Alendronate Is a Specific, Nanomolar Inhibitor of Famesyl Diphosphate Synthase., Arch Biochem Biophys. 2000 Jan 1, 373(1): 231 41

    Google Scholar 

  68. Fisher, J E, Rodan, G A, Reszka, A A, In-Vivo Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway., Endocrinology. 2000 Dec, 141(12): 4793 6

    Google Scholar 

  69. Reszka, A. A; Halasy-Nagy, J; Rodan, G. A, Nitrogen-Bisphosphonates Block Retinoblastoma Phosphorylation and Cell Growth By Inhibiting the Cholesterol Biosynthetic Pathway in a Keratinocyte Model For Esophageal Irritation., Mol. Pharmacol. 2001 Feb; 59(2): 193–202

    PubMed  CAS  Google Scholar 

  70. Rodan GA, Mechanisms of Action of Bisphosphonates, Annual Review of Pharmacology and Toxicology. 1998; 38: 375–388

    Google Scholar 

  71. Sato, M.; Grasser, W.; Endo, N.; Akins, R., and Simmons, H.: Bisphosphonate Action: Alendronate Localization in Rat Bone and Effects on Osteoclast Ultrastructure. J. Clin. Invest. 88: 2095–2105, 1991.

    PubMed  CAS  Google Scholar 

  72. Comparison of MK-217 to Etidronate in Preclinical Studies, MRL, February 20, 1992 [Nonclinical Pharmacology and Toxicology Documentation, Nonclinical Pharmacodynamics, Reference 30].

    Google Scholar 

  73. Flanagan, A. M. and Chambers, T. J.: Dichloromethylenebisphosphonate (CL2MBP) Inhibits Bone Reabsorption Through Injury to Osteoclasts That Reabsorb CL2MBP-Coated Bone. Bone and Mineral 6: 33–43; 1989.

    PubMed  CAS  Google Scholar 

  74. Lundy, M. W; Stauffer, M; Wergedal, J. E; Baylink, D. J; Featherstone, J. D; Hodgson, S. F; Riggs, B. L, Histomorphometric Analysis of Iliac Crest Bone Biopsies in Placebo-Treated Versus Fluoride-Treated Subjects., Osteoporos-Int. 1995 Mar; 5(2): 115–29

    PubMed  CAS  Google Scholar 

  75. Cranney, A, Guyatt, G, Krolicki, N, Welch, V, Griffith, L, Adachi, J D, Shea, B, Tugwell, P, and Wells, G: A Meta Analysis of Etidronate For the Treatment of Postmenopausal Osteoporosis., Osteoporos Int. 2001; 12(2): 140–51

    PubMed  Google Scholar 

  76. Riggs, BL, Hodgson, SF, O’Fallon, WM, Chao, EYS, Wahner, HW, Muhs, JM, Cedel, SL and Melton U III. Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosi, N. Eng. J. Med., 1990, 322 802–809

    CAS  Google Scholar 

  77. Thompson, D D; Seedor, J G; Weinreb, M; Rosini, S; Rodan, G A; Aminohydroxybutane Bisphosphonate Inhibits Bone Loss Due to Immobilization in Rats., J Bone Miner Res. 1990 Mar; 5(3): 279–86

    PubMed  Google Scholar 

  78. Toolan, B C; Shea, M; Myers, E R; Borchers, R E; Seedor, J G; Quartuccio, H; Rodan, G; Hayes, W C; Effects of 4-Amino-l-Hydroxybutylidene Bisphosphonate on Bone Biomechanics in Rats., J Bone Miner Res. 1992 Dec; 7(12): 1399 406

    Google Scholar 

  79. Sato, M; Grasser, W; Endo, N; Akins, R; Simmons, H; Thompson, D D; Golub, E; Rodan, G A; Bisphosphonate Action. Alendronate Localization in Rat Bone and Effects on Osteoclast Ultrastructure., J Clin Invest. 1991 Dec; 88(6): 2095 105

    Google Scholar 

  80. Rodan, G A; Seedor, J G; Balena, R; Preclinical Pharmacology of Alendronate., Osteoporos Int. 1993; 3 Suppl 3: S7–12

    PubMed  Google Scholar 

  81. Yamamoto, M; Markatos, A; Seedor, J G; Masarachia, P; Gentile, M; Rodan, G A; Balena, R; The Effects of the Aminobisphosphonate Alendronate on Thyroid Hormone-Induced Osteopenia in Rats., Calcif Tissue Int. 1993 Oct; 53(4): 278–82

    PubMed  CAS  Google Scholar 

  82. Rodan, G A; Balena, R; Bisphosphonates in the Treatment of Metabolic Bone Diseases., Ann Med. 1993 Aug; 25(4): 373–8

    PubMed  CAS  Google Scholar 

  83. Balena, R; Markatos, A; Gentile, M; Masarachia, P; Seedor, J G; Rodan, G A; Yamamoto, M; The Aminobisphosphonate Alendronate Inhibits Bone Loss Induced By Thyroid Hormone in the Rat. Comparison Between Effects on Tibiae and Vertebrae., Bone. 1993 May Jun; 14(3): 499 504

    Google Scholar 

  84. Wingen, F. and Schmähl, D.: Pharmacokinetics of the Osteotropic Diphosphonate 3-Amino-IHydroxypropane-1,1-Diphosphonic Acid in Mammals. Arzneim. Forsch./Drug Res. 37(9): 1037–1042,1987.

    Google Scholar 

  85. Michael, W. R.; King, W. R., and Wakim, J. M.: Metabolism of Disodium Ethane-I-Hydroxy-1,1Diphosphonate (Disodium Etidronate) in the Rat, Rabbit, Dog and Monkey. Toxicology and Applied Pharmacology 21: 503–515, 1972.

    PubMed  CAS  Google Scholar 

  86. Gural, R. P.: Pharmacokinetics and Gastrointestinal Absorption Behavior of Etidronate. Abstract of Dissertation, University of Kentucky, 1975.

    Google Scholar 

  87. Francis, M. D. and Martodam, R. R.: Chemical, Biochemical, and Medicinal Properties of the Diphosphonates, In: The Role of Phosphonates in Living Systems, Chap. 4, pp. 55–96.

    Google Scholar 

  88. Lauren, L.; Osterman, T., and Karhi, T.: Pharmacokinetics of Clodronate After Single Intravenous, Intramuscular and Subcutaneous Injections in Rats. Pharmacology and Toxicology 69: 365–368, 1991.

    PubMed  CAS  Google Scholar 

  89. Mönkkönen, J.; Ylitalo, P.; Elo, H. A., and Airaksinen, M. M.: Distribution of [14C]Clodronate (Dichloromethylene Bisphosphonate) Disodium in Mice. Toxicology and Applied Pharmacology 89: 287–292, 1987.

    PubMed  Google Scholar 

  90. Mönkkönen, J.: A One Year Follow-Up Study of the Distribution of [14C]Clodronate in Mice and Rats. Pharmacol-ogy and Toxicology 62: 51–53, 1988.

    Google Scholar 

  91. Wingen, F. and Schmähl, D.: Distribution of 3-Amino-1-Hydroxypropane-1,1-Diphosphonic Acid in Rats and Effects on Rat Osteosarcoma. Arzneim. Forsch./Drug Res. 35(10): 1565–1571, 1985.

    CAS  Google Scholar 

  92. Larsson, A. and Rohlin, M.: In-Vivo Distribution of 14C-Labeled Ethylene-l-Hydroxy-1,1Diphosphonate in Normal and Treated Young Rats. An Autoradiographic and Ultra-structural Study. Toxicology and Applied Pharmacology 52: 391–399, 1980.

    PubMed  CAS  Google Scholar 

  93. Mönkkönen, J.; Urtti, A.; Paronen, P.; Elo, H. A., and Ylitalo, P.: The Uptake of Clodronate (Dichloromethylene Bisphosphonate) by Macrophages In-Vivo and In-Vitro. Drug Metabolism and Disposition 17(6): 690–693, 1989.

    PubMed  Google Scholar 

  94. Troehler, U.; BonjourJ.P., and Fleisch, H.: Renal Secretion of Diphosphonates in Rats. Kidney International 8: 6–13, 1975.

    PubMed  CAS  Google Scholar 

  95. Lin, J.H., Bisphosphonates: A Review of their Pharmacokinetic Properties, Bone-. Feb. 1996; 18 (2): 7585

    Google Scholar 

  96. Lin, J.H; Duggan, D.E; Chen, I.W; Ellsworth, R.L, Physiological Disposition of Alendronate, A Potent Anti-Osteolytic Bisphosphonate, in Laboratory Animals., Drug Metab. Dispos. 1991 Sep-Oct; 19(5): 926–32

    CAS  Google Scholar 

  97. Lin, J.H; Chen, I.W; deLuna, F.A, Nonlinear Kinetics of Alendronate. Plasma Protein Binding and Bone Uptake., Drug Metab. Dispos. 1994 May-Jun; 22(3): 400–5

    CAS  Google Scholar 

  98. Porras, A.G; Holland, S.D; Gertz, B.J, Pharmacokinetics of Alendronate., Clin. Pharmacokinet. 1999 May; 36(5): 315–28

    CAS  Google Scholar 

  99. Lin, J.H; Chen, I.W; deLuna, F.A; Hichens, M, Role of Calcium in Plasma Protein Binding and Renal Handling of Alendronate in Hypo-and Hypercalcemic Rats., J. Pharmacol. Exp. Ther. 1993 Nov; 267(2): 670–5

    PubMed  CAS  Google Scholar 

  100. Kino, I; Kato, Y; Lin, J.H; Sugiyama, Y, Renal Handling of Biphosphonate Alendronate in Rats., Biopharm. Drug. Dispos. 1999 May; 20(4): 193–8

    CAS  Google Scholar 

  101. Lin, J.H; Chen, I.W; Deluna, F.A; Hichens, M, Renal Handling of Alendronate in Rats. An Uncharacterized Renal Transport System., Drug Metab. Dispos. 1992 Jul-Aug; 20(4): 608–13

    CAS  Google Scholar 

  102. Lin, J.H., Chen, I.W., and deLuna, F.A., On the Absorption of Alendronate in Rats, J. Pham. Sci. 1994, 83(12), 1741–6

    CAS  Google Scholar 

  103. Tucci, J.R., Tonino, R.P., Emkey, R.D., Peverly, C.A., ‘Cher, U., Santora, A.C, 2nd, Effect of Three Years of Oral Alendronate Treatment In Postmenopausal Women with Osteoporosis, Am. J. Med. 1996 Nov., 101(5): 488–501.

    PubMed  CAS  Google Scholar 

  104. Devogelaer, J.P., Broll, H., Correa-Rotter, R., Cumming, D.C., De-Deuxchaisnes, C.N., Geusens, P., Hosking, D., Jaeger, P., Kaufman, J.M., Leite, M., Leon, J., Liberman, U., Menkes, C.J., Meunier, P.J., Reid, I., Rodriguez, J., Romanowicz, A., Seeman, E., Vermeulen, A., Hirsch, L.J., Lombardi, A., Plezia, K., Santora, A.C., Yates, A.J. and Yuan, W., Oral Alendronate Induces Progressive Increases in Bone Mass of the Spine, Hip, and Total Body over 3 Years in Postmenopausal Women with Osteoporosis, Bone,1996 Feb., 18(2): 141–50.

    PubMed  CAS  Google Scholar 

  105. Nevitt, M.C., Thompson, D.E., Black, D.M., Rubin, S.R., Ensrud, K., Yates, A.J., and Cummings, S.R, Effect of Alendronate on Limited-Activity Days and Bed-Disability Days Caused by Back Pain In Postmenopausal Women with Existing Vertebral Fractures. Fracture Intervention Trial Research Group. Arch. Intern. Med. 2000 Jan 10., 160(1): 77–85.

    Google Scholar 

  106. Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C., Vogt, T., Wallace, R., Yates, A.J., and LaCroix, A.Z, Effect of Alendronate on Risk of Fracture in Women with Low Bone Density but Without Vertebral Fractures: Results from the Fracture Intervention Trial. JAMA. 1998 Dec 23–30., 280(24): 23–30.

    PubMed  CAS  Google Scholar 

  107. Levis, S., Quandt, S.A., Thompson, D., Scott, J., Schneider, D.L., Ross, P.D., Black, D., Suryawanshi, S., HochbergM.and Yates, J, Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial. J. Am. Geriatr. Soc. 2002 Mar., 50(3): 409–15.

    PubMed  Google Scholar 

  108. Greenspan, S.L., Holland, S., Maitland-Ramsey, L., Poku, M., Freeman, A., Yuan, W., Kher, U., and Gertz, B., Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc. Assoc. Am. Physicians. 1996 May., 108(3): 230–8.

    PubMed  CAS  Google Scholar 

  109. Caniggia, A. and Gennari, C.: Kinetics and Intestinal Absorption of [32P]EHDP in Man. Calcif. Tissue Res. 22(Suppl): 428–429, 1977.

    Google Scholar 

  110. Daley-Yates, P. T.; Dodwell, D. J.; Pongchaidecha, M.; Coleman, R. E., and Howell, A.: The Clearance and Bioavailability of Pamidronate in Patients With Breast Cancer and Bone Metastases. Calcif. Tissue Int. 49: 433–435, 1991.

    CAS  Google Scholar 

  111. Leyvraz, S.; Hess, U.; Flesch, G.; Bauer, J.; Hauffe, S.; Ford, J. M., and Burckhardt, P.: Pharmacokinetics of Pamidronate in Patients With Bone Metastases. JNCI 84(10): 788–792, 1992.

    PubMed  CAS  Google Scholar 

  112. Pentikäinen, P. J.; Elomaa, I.; Nurmi, A.-K., and Kärkkäinen, S.: Pharmacokinetics of Clodronate in Patients With Metastatic Breast Cancer. International J. of Clinical Pharmacology, Therapy and Toxicology 27(5): 222–228, 1989.

    Google Scholar 

  113. Wiedmer, W. H.; Zbinden, A. M.; Trechsel, U., and Fleisch, H.: Ultrafiltrability and Chromatographic Properties of Pyrophosphate, 1-Hydroxyethylidene-1,l-Bisphosphonate, and Dichloromethylenebisphosphonate in Aqueous Buffers and in Human Plasma. Calcif. Tissue Int. 35: 397–400,1983.

    CAS  Google Scholar 

  114. Conrad, K. A. and Lee, S. M.: Clodronate Kinetics and Dynamics. Clin. Pharmacol. Ther. 30(1): 114–120, 1981.

    PubMed  CAS  Google Scholar 

  115. Gural, R. P.: Pharmacokinetics and Gastrointestinal Absorption Behavior of Etidronate. Abstract of Disserta-tion, Universi-ty of Kentucky, 1975.

    Google Scholar 

  116. Recker, R. R. and Saville, P. D.: Intestinal Absorption of Disodium Ethane-l-Hydroxy-1,1-Diphosphonate (Disodium Etidronate) Using a Deconvolution Technique. Toxicology and Applied Pharmacology 24: 580–589, 1973.

    PubMed  CAS  Google Scholar 

  117. Powell, J. H. and DeMark, B. R.: Clinical Pharmacokinetics of Diphosphonates. in: Bone Resorption, Metastasis, and Diphosphonates, Garattini, S. ed., Raven Press, New York, 1985, pp. 41–49.

    Google Scholar 

  118. Fitton, A. and McTavish, D.: Pamidronate: A Review of its Pharmacological Properties and Therapeutic Efficacy in Resorptive Bone Disease. Drugs 41(2): 289–318, 1991.

    PubMed  CAS  Google Scholar 

  119. Yakatan, G. J.; Poynor, W. J.; Talbert, R. L.; Floyd, B. F.; Slough, C. L.; Ampulski, R. S., and Benedict, J. J.: Clodronate Kinetics and Bioavailability. Clin. Pharmacol. Ther. 31(3): 402–410, 1982.

    CAS  Google Scholar 

  120. Hanhijärvi, H.; Elomaa, I.; ‘Carlsson, M., and Lauren, L.: Pharmacokinetics of Disodium Clodronate After Daily Intravenous Infusions During Five Consecutive Days. International J. of Clinical Pharmacology, Therapy and Toxicology 27(12): 602–606, 1989.

    Google Scholar 

  121. FogelmanI.;Smith, L.; Mazess, R.; Wilson, M. A., and Bevan, J. A.: Absorption of Oral Diphosphonate in Normal Subjects. Clinical Endocrinology 24: 57–62, 1986.

    PubMed  CAS  Google Scholar 

  122. Kline, W. F.; Matuszewski, B. K., and Bayne, W. F.: Determina-tion of 4-Amino-I-Hydroxybutane-1,1Bisphosphonic Acid in Urine by Automated Pre-Column Derivatization With 2,3-Naphthalene Dicarboxyaldehyde and High-Performance Liquid Chromatography With Fluorescence Detection. J. Chromatogr. (Biomed. Appl.) 534: 139–149, 1990.

    CAS  Google Scholar 

  123. Kline, W. F. and Matuszewski, B. K.: Improved Determination of the Bisphosphonate Alendronate in Human Plasma and Urine by Automated Precolumn Derivatization and High Performance Liquid Chromatography With Fluorescence and Electrochemical Detection. J. Chromatogr. (Biomed. Appl.) 583: 183–193, 1992.

    CAS  Google Scholar 

  124. Porras, A.G., Holland, S.D., Gertz, B.J., Pharmacokinetics of Alendronate, Clin. Pharmacokinet. May 1999, 36 (5): 315–32

    CAS  Google Scholar 

  125. Cocquyt, V., Kline, W.F., Gertz, B.J., Van Belle, S.J.P., Holland, S.D., DeSmet, M., Quan, H., Vyas, K.P., Zhang, K.Y.E., De Greve, J., Porras, A.G., Pharmacokinetics of Intravenous Alendronate, J. Clin. Pharm., Apr 1999; 39 (4): 385–393

    CAS  Google Scholar 

  126. Gibaldi, M. and Perrier, D.: Chapter 11: Noncompartmental Analysis Based on Statistical Moment Theory, in: Pharmacokinetics. 2nd ed., Marcel Dekker, Inc., New York and Basel, 1982, pp. 409–417.

    Google Scholar 

  127. Khan, S.A., Kanis, J.A., Vasikaran, S., Kline, W.F., Matuszewski, B.K., McCloskey, E.V., Beneton, M.N.C., Gertz, B.J., Sciberras, D.G., Holland, S.D., Orgee, J., Coombes, G.M., Rogers, S.R., Porras, A.G, Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis, J. Bone Mineral Res., Oct 1997., 12 (10): 1700–1707

    CAS  Google Scholar 

  128. Gertz, B.J., Holland, S.H., Kline, W.F., Matuszewski, B.K., Freeman, A., Quan, H., Lasseter, K.C., Mucklow, J.C., Porras, A.G., Studies of the Oral Bioavailability of Alendronate, Clin. Pharm. Ther. Sep 1995., 58 (3): 288–298

    CAS  Google Scholar 

  129. Altman, D. F.: The Effect of Age on Gastrointestinal Function. Sleisenger, M. H., Fordtran, J. S., eds., In: Gastrointestinal Disease, Volume 1, Pathophysiology, Diagnosis, Management, 4th ed., W. B. Saunders Company, Philadelphia, pp. 162–169.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Merck Research Laboratories, West Point, PA, USA

    Arturo G. Porras

  2. Merck Research Laboratories, Rahway, NJ, USA

    Barry J. Gertz

Authors
  1. Arturo G. Porras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry J. Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Aventis Pharmaceuticals, Inc., Bridgewater, New Jersey, USA

    Rajesh Krishna Ph.D., F.C.P.

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Porras, A.G., Gertz, B.J. (2004). The Role of Clinical Pharmacology and of Pharmacokinetics in The Development of Alendronate - A Bone Resorption Inhibitor. In: Krishna, R. (eds) Applications of Pharmacokinetic Principles in Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9216-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9216-1_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4842-9

  • Online ISBN: 978-1-4419-9216-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation